A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 13, Pages 4811
Publisher
MDPI AG
Online
2020-07-07
DOI
10.3390/ijms21134811
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
- (2020) Yayoi Nishida et al. BMC Pharmacology & Toxicology
- Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus
- (2019) Shinji Kishimoto et al. AMERICAN JOURNAL OF HYPERTENSION
- Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention
- (2019) Sho-ichi Yamagishi CIRCULATION JOURNAL
- Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes
- (2019) Makoto Ohara et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sex disparity in cardiovascular mortality rates associated with diabetes
- (2018) Sho-ichi Yamagishi DIABETES-METABOLISM RESEARCH AND REVIEWS
- Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4
- (2018) Kumiko Kaifu et al. MICROVASCULAR RESEARCH
- Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population
- (2018) Robert P. van Waateringe et al. DIABETOLOGIA
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients
- (2018) Michishige Terasaki et al. International Journal of Endocrinology
- Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)
- (2016) Tomoya Mita et al. DIABETES CARE
- Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol
- (2016) Lei Xu et al. Lipids in Health and Disease
- Association of Sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study
- (2015) Tsung-Yuan Yang et al. ACTA DIABETOLOGICA
- Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
- (2015) Sho-ichi Yamagishi et al. Cardiovascular Diabetology
- Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
- (2015) Tomoya Mita et al. DIABETES CARE
- Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
- (2015) Nobuhiro Tahara et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis
- (2015) Takanori Matsui et al. LABORATORY INVESTIGATION
- Unknown
- (2015) Sho-ichi Yamagishi et al. MOLECULAR MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Advanced Glycation End Products Are Associated With Incident Cardiovascular Events in Individuals With Type 2 Diabetes: A Case-Cohort Study With a Median Follow-up of 10 Years (EPIC-NL)
- (2014) Nordin M.J. Hanssen et al. DIABETES
- Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is a Predictor of Endothelial Function
- (2014) Masato Kajikawa et al. DIABETES CARE
- DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway
- (2013) Yao Dai et al. ACTA DIABETOLOGICA
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype
- (2013) Nordin M.J. Hanssen et al. EUROPEAN HEART JOURNAL
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
- (2013) Michishige Terasaki et al. PLoS One
- Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation
- (2012) S. Allahverdian et al. CARDIOVASCULAR RESEARCH
- Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
- (2012) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography
- (2012) N. Tahara et al. DIABETES CARE
- Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties
- (2012) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Effects of PKF275-055, a dipeptidyl peptidase–4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E–null mice
- (2012) Michishige Terasaki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
- (2012) Yukinori Nogi et al. PLoS One
- Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
- (2011) J. W. Nin et al. DIABETES CARE
- Advanced glycation end products downregulate glucokinase in mice
- (2011) Hongsoo Jung et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells
- (2011) Y. Ishibashi et al. HORMONE AND METABOLIC RESEARCH
- DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice
- (2011) Nga N Ta et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women
- (2009) Bente K. Kilhovd et al. ATHEROSCLEROSIS
- Plasma Carboxymethyl-Lysine, an Advanced Glycation End Product, and All-Cause and Cardiovascular Disease Mortality in Older Community-Dwelling Adults
- (2009) Richard D. Semba et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now